When you’ve just lost a limb, or your spine is fractured, the likelihood of recurrence is quite high.
But it is also possible that you may be able to avoid recurrence.
In a new study, researchers found that people with a spinal cord injury, particularly the spinal cord subluxation, were able to have more normal life outcomes after a short recovery period.
The study, published online in the journal Neurology, also found that patients with this injury had a reduced risk of developing dementia, Parkinson’s disease and Alzheimer’s disease.
For decades, scientists have been exploring ways to treat and treat people with spinal cord disorders with new and better drugs, including a new drug, pembrolizumab, which targets the proteins that cause the subluxations.
Now, the new study suggests that pembolizumacin might be able help to reverse some of the damage caused by these subluxated discs.
Pembolosumab works by targeting the proteins responsible for the sublattices, or openings that allow the spine to bend and flex.
The proteins in the subligaments, called spines, are responsible for movement of the spine.
They are part of the vertebral column and help control the spine’s rotation and its ability to bend.
The researchers, led by Dr. Michael A. Sperry, an associate professor at Harvard Medical School and the Brigham and Women’s Hospital in Boston, found that when people had the pembolinib drug administered to the spine, the spines of the patients healed, and the researchers then found that there was a significant reduction in the amount of abnormal spine changes, as well as a decrease in the likelihood that a spinal injury would recur.
The researchers believe that this could be a potential new therapeutic option, especially since many patients with subluxates do not recover well.
“Our results show that a pembolineib drug that targets a protein known as spines can reduce spine injury and return normal functional abilities after a brief recovery period,” Dr. Soper said.
“The data also suggests that a longer-term trial is needed to determine whether a longer duration of therapy will help to prevent long-term disability.
While pembolsumab was not tested in humans, Dr. A. Michael Wannamaker, a professor of neurology at the University of Pennsylvania, and his colleagues have found that it has similar effects on the brain.
More research is needed, but it is thought that a long-lasting, safe treatment of subluxed discs may have value for patients with spinal injury, and for people with other spinal cord diseases.
If you or someone you know is suffering from a spinal injuries injury, you can call the National Spine Institute’s helpline for free help.